PAVM — PAVmed Inc.

PAVmed Q4 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Revenue: Lucid Diagnostics reported approximately $1.5 million in EsoGuard revenue for Q4 2025, reflecting a 24% increase from Q3 2025. EsoGuard test volume increased by 29% to 3,664 tests.
• Cash Burn: PAVmed reported a cash burn rate of $1.5 million for Q4, primarily driven by Veris operating costs and development expenses for the implantable device.
• Balance Sheet: PAVmed's equity method investment in Lucid was valued at $34 million, up $8.5 million year-over-year due to a 33% increase in Lucid's stock. The company completed a recapitalization that improved its financial stability, resulting in total assets exceeding $100 million post-financing.
• Net Loss: The GAAP net loss for Q4 was $2.8 million, with a non-GAAP loss of $942,000, primarily due to development costs and franchise taxes.

2. Strategic Updates and Business Highlights

• Capital Structure: PAVmed completed a significant recapitalization in February 2026, removing toxic convertible securities and establishing a clean capital structure, positioning the company for growth.
• Lucid Diagnostics: PAVmed remains Lucid's largest shareholder, holding approximately 18% of common shares. Lucid secured a contract with the U.S. Department of Veterans Affairs, enhancing its market access.
• Veris Health: Veris is advancing its cancer care platform and is on track for FDA submission of its implantable device later in 2026. The integration with Ohio State University (OSU) is progressing positively, with a target of enrolling 1,000 patients in the first year.
• MedTech Portfolio Relaunch: PAVmed is relaunching its medical device portfolio under new leadership, focusing on technologies related to gastroesophageal diseases, including a licensed endoscopic imaging technology from Duke University.

3. Forward Guidance and Outlook

• PAVmed is optimistic about its strategic positioning and operational momentum as it enters 2026. The company aims to leverage its strengthened balance sheet to explore new opportunities in medical devices and diagnostics.
• The focus will be on completing the FDA submission for Veris's implantable device and expanding commercial partnerships, particularly after achieving key milestones with OSU.

4. Bad News, Challenges, or Points of Concern

• Operational Risks: The company faces challenges in managing its cash burn and ensuring adequate funding for ongoing development projects, particularly for Veris's implantable device.
• Market Competition: PAVmed must navigate competitive pressures in the digital health and medical device sectors, particularly as it seeks to expand its offerings and partnerships.
• Execution Risks: The successful rollout of new technologies and partnerships hinges on effective execution and integration, particularly with OSU and other potential partners.

5. Notable Q&A Insights

• Commercial Relationship with OSU: PAVmed is tracking patient enrollment and departmental integration as key metrics for the success of its partnership with OSU. The goal is to exceed the target of 1,000 patients in the first year.
• Integration of New Tools: Discussions are ongoing with OSU regarding the development of AI-based clinical decision support tools, which will require extensive data and resources.
• Future of Medical Device Portfolio: PAVmed is open to inquiries across various medical technologies, with a particular interest in gastroesophageal products, reflecting its historical expertise in this area.

Overall, PAVmed is positioned for growth following a significant restructuring, with promising developments in its subsidiaries, although it must remain vigilant about operational and market challenges.